Business Context and Reporting Period
This Form 8-K Current Report was filed by Entrada Therapeutics, Inc. on August 10, 2023, covering events occurring on August 4, 2023. The Company is a Delaware corporation with its principal executive offices in Boston, MA, and its common stock trades on The Nasdaq Global Market under the symbol "TRDA". The filing primarily addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. As a Current Report focused on Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers), it contains no financial performance data for the period.
Material Changes
The material change reported is the appointment of Gina Chapman to the Board of Directors as a Class III director, effective September 1, 2023. She will serve until the 2024 annual meeting of stockholders or until her successor is elected. Additionally, Ms. Chapman was appointed to the Nominating and Corporate Governance Committee effective September 1, 2023.
Compensation and Governance Details
- Initial Grant: Ms. Chapman will receive a stock option to purchase the lesser of a value of $500,000 or 32,000 shares of Common Stock, effective September 1, 2023. This option vests in equal monthly installments over three years, contingent on continuous service.
- Annual Fees: She will receive an annual director fee of $40,000 and an annual committee fee of $4,000 for her service on the Nominating and Corporate Governance Committee.
- Future Grants: Beginning with the 2024 Annual Meeting, she is eligible for an annual stock option grant equal to the lesser of a value of $250,000 or 16,000 shares. These future options vest in full upon the earlier of the first anniversary of the grant date or the next Annual Meeting.
- Indemnification: Ms. Chapman will enter into the Company's standard form of indemnification agreement.
The filing confirms there are no family relationships between Ms. Chapman and other directors or officers, and no related person transactions exist.
Investor Verification Checklist
- Verify the effective date of Ms. Chapman's board appointment (September 1, 2023) against the Company's calendar of upcoming meetings.
- Review the attached Press Release (Exhibit 99.1) for additional biographical details on Ms. Chapman's qualifications.
- Confirm the specific vesting schedule and exercise price of the initial 32,000 share option grant in subsequent filings or the Company's equity incentive plan documents.
- Monitor the Company's 2024 Annual Meeting proxy statement for the execution of the recurring annual stock option grant.